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A B S T R A C T
Purpose
The prognosis of gastric cancer (GC) is poor, and the molecular pathogenesis players are vastly
unknown. Surgery remains the primary option in GC treatment. The aim of this study was to
investigate the impact of somatic CDH1 alterations in prognosis and survival of patients with GC.
Patients and Methods
A series of patients with sporadic and familial GC (diffuse and intestinal; n  246) were analyzed for
somatic CDH1 mutations, promoter hypermethylation, and loss of heterozygosity (LOH) by polymer-
ase chain reaction sequencing. E-cadherin protein expression was determined by immunohistochem-
istry. Associations between molecular, clinicopathologic, and survival data were analyzed.
Results
CDH1 somatic alterations were found in approximately 30% of all patients with GC. Both
histologic types of sporadic GC displayed LOH in 7.5%, mutations in 1.7%, and hypermethylation
in 18.4% of patients. Primary tumors from hereditary diffuse GC, lacking germline CDH1
alterations, showed exclusively CDH1 promoter hypermethylation in 50% of patients. Familial
intestinal GC (FIGC) tumors showed LOH in 9.4% and hypermethylation in 17.0%. CDH1
alterations did not associate with a particular pattern of E-cadherin expression. Importantly, the
worst patient survival rate among all GCs analyzed was seen in patients with tumors carrying
CDH1 structural alterations, preferentially those belonging to FIGC families.
Conclusion
CDH1 somatic alterations exist in all clinical settings and histotypes of GC and associate with
different survival rates. Their screening at GC diagnosis may predict patient prognosis and is likely
to improve management of patients with this disease.
J Clin Oncol 31:868-875. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Gastric cancer (GC) is the second leading cause of
cancer-related deaths worldwide, affecting close to
one million people per year.1 The majority of pa-
tients with GC present with advanced disease at di-
agnosis (stages III and IV), rendering the prognosis
extremely poor, with a 5-year overall survival rate of
less than 25%.2-4 Most patients with GC are asymp-
tomatic during the early stages of disease, thus delay-
ing the initial diagnosis. Although, some studies
have pinpointed improvements on patient survival
with perioperative and adjuvant treatment modali-
ties, surgical resection is still the primary curative
treatment for localized GC; however, less than 50%
of patients are eligible for resection.5,6 During the
last decade, several genetic and epigenetic changes
underlying gastric carcinogenesis have been eluci-
dated.7,8 Nonetheless, their clinical usefulness is
limited because of the lack of systematic genetic-
clinical correlations.
GC is histologically classified into two major
types, intestinal and diffuse.9 The intestinal type is
characterized by well-differentiated glandular struc-
tures, whereas the diffuse type consists of individu-
ally infiltrating neoplastic cells that may have signet
ring morphology, does not form glandular struc-
tures, and has a poorer patient prognosis.10,11 The
majority of GCs (90%) appear in a sporadic setting.
The remaining 10% of GCs show familial clustering,
and of these, only 1% to 3% constitute hereditary
forms.12 Among GCs with familial aggregation and
with histology information, the following specific
syndromes can be identified: familial intestinal GC
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 31  NUMBER 7  MARCH 1 2013
868 © 2013 by American Society of Clinical Oncology
Downloaded from ascopubs.org by 193.136.52.11 on January 19, 2018 from 193.136.052.011
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
(FIGC) and hereditary diffuse GC (HDGC; Online Mendelian Inher-
itance in Man No. 137215).13 So far, no germline defects have been
associated with FIGC, whereas germline mutations and deletions of
E-cadherin (CDH1) are the underlying genetic defect in 45% of fam-
ilies with clinical diagnosis of HDGC.14-16
Furthermore, 70% of CDH1 mutation–negative HDGC pro-
bands display germline monoallelic CDH1 RNA downregulation (al-
lelic imbalance) reinforcing the role of CDH1 locus in this disease.17
HDGC tumors appear when complete somatic CDH1 inactivation is
acquired, leading to reduced or absent E-cadherin expression.18,19
This occurs through second hit mechanisms, pursuing the Knudson’s
model of tumor suppressor gene inactivation.20,21 CDH1 promoter
hypermethylation is the most frequent second hit inactivation mech-
anism in HDGC primary tumors (50% to 70% of tumors), whereas a
second mutation or deletion (loss of heterozygosity [LOH]/intragenic
deletions) was less frequently identified.22-24
In the sporadic context, the frequency of CDH1 somatic muta-
tions is controversial, and percentages between 3% and greater than
50% have been reported for GCs with a diffuse component.25-28 LOH
at the CDH1 locus was noted in diffuse and intestinal histotypes, with
rates ranging from 11% to 39% and 36% to 46%, respectively.29-31
Epigenetic silencing through CDH1 promoter hypermethylation has
been reported in frequencies that vary from 50% to 83% in diffuse
tumors and from 6.25% to 50% in intestinal tumors.28-32 Importantly,
the presence of concomitant CDH1 inactivation mechanisms was
rarely described in this setting.28,29,33 Nevertheless, most of these stud-
ies have been limited by the series size, the type of molecular mecha-
nisms studied, different methodologic approaches, and the lack of
extensive correlations with clinical parameters, thus hampering po-
tential translation of genetic data into medical practice.34
The goal of this study was to analyze the impact of somatic CDH1
alterations in prognosis and survival of patients with GC. In this study,
we performed a comprehensive analysis of somatic CDH1 mutations,
LOH, and promoter hypermethylation in 246 patients with sporadic
and familial GC. Additionally, we analyzed the relationship between
somatic alterations underlying CDH1 inactivation and survival rates,
clinicopathologic characteristics of patients with GC, and E-cadherin
expression in tumors.
PATIENTS AND METHODS
Patients
All 246 patients with GC enrolled onto this study were admitted at the
Division of General Surgery and Surgical Oncology, University of Siena (Siena,
Italy) and were classified as having sporadic (n  174) or familial (n  72) GC.
Patients with familial GC were classified as having HDGC (n  19) or FIGC
(n  53) using clinical criteria defined by the International Gastric Cancer
Linkage Consortium13 (Appendix Table A1, online only). The presence of
CDH1 germline mutations was discarded in all patients with HDGC in this
cohort. Patients with GC classification more than pT1N were candidates for
adjuvant chemotherapy using standard protocols. Prospectively collected clin-
icopathologic and follow-up data were available. The median follow-up time
for surviving patients was 92.1 months. Informed consent was obtained from
all patients, and the study was approved by the hospital’s ethics committee
(Appendix, online only).
DNA Extraction
Tissue areas for DNA extraction were histologically verified to contain a
minimum of 70% to 80% of neoplastic cells. DNA was isolated from frozen
material using the Puregene DNA Purification Kit (Gentra Systems, Minne-
apolis, MN).
CDH1 Promoter Hypermethylation Analysis
CDH1 promoter methylation analysis was carried out in 160 base pairs
upstream of the translation start site, encompassing 17 CpG sites, as previously
described23 (Appendix, online only). Primer sequences are listed in Appendix
Table A2 (online only).
CDH1 Somatic Mutation Screening
Fifty nanograms of tumor DNA from 86 diffuse GCs were subjected to
mutation screening at the CDH1 hotspot region (exons 7 to 10), as previously
described.23 Each mutation was confirmed by an independent polymerase
chain reaction amplification followed by sequencing analysis. Primer se-
quences are listed in Appendix Table A2 (online only).
LOH Analysis
LOH analysis was performed using three intragenic CDH1 markers (the
promoter 161C/A [rs16260], the exon 13 2076T/C [rs1801552], and the
3-untranslated region single-nucleotide polymorphisms [rs1801026]) and
three proximal and distal microsatellite markers (D16S3025, D16S496, and
D16S3067) flanking the CDH1 locus, as described.23 Only informative mark-
ers were considered for LOH analysis, and positive samples were repeated
twice (Appendix). Primer sequences are listed in Appendix Table A2
(online only).
E-Cadherin Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues comprising 207 GCs were
stained with mouse E-cadherin monoclonal antibody HECD-1 (dilution
1:200; Zymed, San Francisco, CA) followed by incubation with avidin-biotin
complex and diaminobenzidine. E-cadherin immunoreactivity was evaluated
on tumor and normal tissues considering the predominant expression pat-
tern—normal (complete membrane staining), aberrant (cytoplasmic and het-
erogeneous staining), or absent (no staining).
Statistical Analysis
Analyses were performed using commercially available statistical soft-
ware (SPSS, version 14.0; SPSS, Chicago, IL). Statistical associations between
clinicopathologic characteristics and CDH1 somatic alterations were assessed
using the 2 test for categorical variables and the t test or analysis of variance for
continuous variables. Survival curves were estimated using the Kaplan-Meier
method and were compared using the log-rank test. Multivariate analysis was
performed using a Cox proportional hazards regression model by considering
the following risk factors: sex, age (older v the median age or younger), tumor
location (other v antrum), Lauren histotype (nonintestinal v intestinal), depth
of tumor invasion (pT2-4 v pT1), lymph node involvement (pN1-3 v pN0),
presence of systemic metastasis (M1 v M0), and R category (R1 or R2 v R0).
Postoperative mortality was assessed, with deaths unrelated to tumor recur-
rence considered censored observations at the time of death. P  .05 was
considered statistically significant.
RESULTS
After screening of somatic CDH1 promoter hypermethylation, LOH,
and mutations in exons 7 to 10, GCs were clustered in the following
groups regarding CDH1 alterations: patients with methylation only
(named epigenetic); patients with LOH or mutation, with/without
methylation (named structural); and patients without CDH1 altera-
tions (named negative).
CDH1 Structural and Epigenetic Alterations in
Overall GC
Overall, 77 (31.3%) of 246 GCs carried somatic CDH1 altera-
tions. Epigenetic alterations were found in 51 (20.7%) of 246 GCs, and
structural alterations were detected in 26 (10.6%) of 246 GCs. Specif-
ically within structural alterations, LOH alone was detected in 18
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(7.3%) of 246 GCs, mutation alone was found in three (1.2%) of 246
GCs (c.1109AG [p.Asp370Gly], c.IVS95GA, and c.1105_1106
insACCAAC), and five (2%) of 246 GCs presented LOH concomi-
tantly with CDH1 promoter hypermethylation (Table 1, Appendix
Figs A1 and A2, online only).
Patients with tumors with CDH1 structural alterations displayed
poorer overall survival (P  .017; Fig 1; all cases) than patients with
negative tumors or tumors carrying CDH1 epigenetic alterations.
CDH1 Structural and Epigenetic Alterations in
Different Clinical Settings and Histologic Types of GC
We evaluated the distribution of somatic CDH1 alterations
among clinical settings (sporadic and familial) and histotypes (intes-
tinal and diffuse) of GC and correlated these findings with overall
patient survival. The overall frequency of CDH1 alterations was simi-
lar in sporadic (51 of 174 tumors; 29.3%) and familial (26 of 72
tumors; 36.1%) tumors (Table 1). Specifically within the sporadic
Table 1. Epigenetic and Structural CDH1 Alterations in Patients With Sporadic and Familial GCs
Setting and
Histologic Type
No. of
Patients
CDH1 Alterations
Overall
Frequency of
CDH1
Alterations
Negative
Patients
Epigenetic
Methylation
Only
Structural
LOH Only
Mutation
Only Concomitant
No. % No. % No. % No. % No. % No. %
Sporadic
Intestinal 107 15 14.0 10 9.3 0† 0.0 3‡ 2.8 28 26.2 79 73.8
Diffuse/mixed 67 17 25.4 3 4.5 3 4.5 0 0.0 23 34.3 44 65.7
Total 174 32 18.4 13 7.5 3 1.7 3 1.7 51 29.3 123 70.7
Familial
FIGC§ 53 9 17.0 5 9.4 0† 0.0 2‡ 3.8 16 30.2 37 69.8
HDGC§ 19 10 52.6 0 0.0 0 0.0 0 0.0 10 52.6 9 47.4
Total 72 19 26.4 5 6.9 0 0.0 2 2.8 26 36.1 46 63.9
Total 246 51 20.7 18 7.3 3 1.2 5 2.0 77 31.3 169 68.7
Abbreviations: FIGC, familial intestinal gastric cancer; GC, gastric cancer; HDGC, hereditary diffuse gastric cancer; LOH, loss of heterozygosity.
This frequency was calculated assuming that intestinal GCs were negative for somatic CDH1 mutations (three of 174 GCs; 1.7%).
†Intestinal GCs were assumed to lack CDH1 somatic mutations.
‡Methylation and LOH occurred concomitantly.
§A statistically significant association was found when comparing FIGCs or HDGCs for three classes of alterations—patients with epigenetic alterations only,
patients with structural alterations, and negative patients (P  .005, Fisher’s exact test; Appendix Table A3, online only)—because more than 50% of HDGC tumors
carry CDH1 promoter methylation. LOH was defined when the LOH index was greater than or less than 1.04  0.13 for D16S3025, 1.0  0.67 for D16S496, and
1.06  0.11 for D16S3067 as reference.
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Fig 1. Kaplan-Meier curves showing the probability of overall survival for patients with gastric cancer (GC), according to CDH1 alterations (epigenetic, structural, or
negative) and stratified according to GC clinical settings (sporadic or familial) and histologic type (intestinal or diffuse).
Corso et al
870 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 193.136.52.11 on January 19, 2018 from 193.136.052.011
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
setting, 32 (18.4%) of 174 GCs displayed epigenetic alterations and 19
(10.9%) of 174 GCs presented structural alterations. Within the famil-
ial setting, 19 (26.4%) of 72 GCs harbored epigenetic alterations,
whereas seven (9.7%) of 72 GCs displayed structural alterations (Table
1; Appendix Table A3, online only). No significant correlation was
observed between GC clinical settings and overall/specific CDH1 al-
terations (P  .05; Appendix Table A4, online only). However, pa-
tients with tumors with CDH1 structural alterations, from both
sporadic and familial settings, had a poorer survival rate than patients
with negative tumors or with CDH1 epigenetic alterations (P  .046
and P  .002, respectively; Fig 1).
Regarding GC histotypes independent of the clinical setting, the
overall frequency of CDH1 alterations was 27.5% (44 of 160 GCs) in
intestinal GCs and 38.4% (33 of 86 GCs) in diffuse GCs (Table 2).
Whereas within intestinal tumors, 15% carried epigenetic alterations
and 12.5% carried structural alterations, in diffuse tumors, 31.4%
carried epigenetic alterations and 7% carried structural alterations.
Although diffuse tumors carried epigenetic alterations more often
than structural alterations (P  .007; Table 2), these molecular fea-
tures did not confer different overall survival (P  .230, Fig 1). In
contrast, and although intestinal tumors carried similar frequencies of
epigenetic and structural alterations, Kaplan-Meier plots showed that
patients with intestinal tumors carrying structural alterations had a
lower probability of survival than patients with intestinal tumors neg-
ative for or carrying CDH1 epigenetic alterations (P  .041; Fig 1). In
fact from the 26 GCs with structural alterations, 20 (76.9%) were of the
intestinal type (P  .007; Table 3).
We observed that within sporadic and familial settings, pa-
tients with tumors carrying structural alterations had worse overall
survival. Moreover, we also verified that patients with intestinal-
type tumors carrying structural alterations, independent of the
clinical setting, had worse overall survival. Therefore, we next
assessed whether the worse overall survival of patients with intes-
tinal tumors with structural alterations was a feature of familial
and/or sporadic settings.
Intestinal tumors belonging to sporadic and familial (FIGC) set-
tings did not differ in the frequency of epigenetic (14% sporadic, 17%
FIGC) and structural alterations (12.1% sporadic, 13.2% FIGC; Table
1, Appendix Table A3, Fig 2). Nonetheless, the Kaplan-Meier plots
showed statistical differences in terms of overall survival only for
patients belonging to FIGC families. The patients with FIGC carrying
tumors with structural alterations had the poorest survival rate
(P  .001; Fig 2). Although it did not reach statistical significance
(P  .148), patients with intestinal tumors belonging to the sporadic
setting and carrying structural alterations also had a poorer survival
rate compared with patients carrying negative/epigenetic alterations
(Table 1, Appendix Table A3, Fig 2).
Within diffuse-type tumors, tumors belonging to the sporadic
setting displayed epigenetic (25.4%) and structural (8.9%) alterations,
whereas HDGC tumors (52.6%) harbored exclusively epigenetic al-
terations (Table 1, Appendix Table A3). Kaplan-Meier plots showed
no association between the type of CDH1-specific alterations and
overall survival of patients with sporadic diffuse or HDGC tumors
(P  .259 and P  .631, respectively; Fig 2). However, despite the
lack of statistical significance, the few patients with sporadic
diffuse-type tumors carrying structural alterations had the lowest
survival rates (P  .259; Fig 2).
CDH1 Structural and Epigenetic Alterations and
Clinicopathologic Features of GC
We next tried to understand whether the presence of overall or
specific CDH1 alterations correlated with clinicopathologic parame-
ters of tumors and patients (Table 3). This analysis revealed that
patients with tumors carrying overall CDH1 alterations displayed
significantly more frequently lymph node metastases (P  .021) and
more advanced tumors (P  .029), in particular invasive stage III. The
other clinicopathologic parameters, including age, sex, liver or perito-
neal metastases, radicality of resection, extent of gastrectomy, lymph-
adenectomy, depth of invasion, familial aggregation, and even Lauren
histotype, were not significantly associated with the presence of overall
CDH1 alterations (Table 3).
When considering the specific type of CDH1 alterations in the
different GC groups (epigenetic v structural v negative), we observed
that patients carrying tumors displaying epigenetic CDH1 alterations
more frequently had the diffuse histotype (P  .007) and 84.3% had
lymph node metastases (P  .02). We also observed that patients
carrying tumors with structural CDH1 alterations more frequently
had intestinal histotype (20 of 26 patients, 76.9%; P  .007) and were
mainly males (23 of 26 patients, 88.5%; P .004), and 46.1% had been
submitted to R1/2 resections (compared with 21.6% with epigenetic
alterations and 24.8% negative for alterations; P  .09; Table 3).
CDH1 Structural and Epigenetic Alterations and
E-Cadherin Immunoexpression Pattern
We also evaluated E-cadherin expression and correlated it with
tumor histology and CDH1 alterations. Of 207 patients analyzed,
73.4% showed aberrant expression, 14.5% displayed complete loss of
E-cadherin, and 12.1% retained the protein at the cell membrane
(Table 4). In both sporadic and familial settings, there was a significant
Table 2. Epigenetic and Structural CDH1 Alterations in Intestinal and Diffuse GCs
GC Histotype No. of Patients
CDH1 Alterations
Overall
Frequency of
CDH1
Alterations Negative
P
Epigenetic Structural Negative
PNo. % No. % No. % No. % No. %
Intestinal 160 24 15.0 20 12.5 116 72.5 .007 44 27.5 116 72.5 .108
Diffuse 86 27 31.4 6 7.0 53 61.6 33 38.4 53 61.6
Abbreviation: GC, gastric cancer.
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association between complete loss of E-cadherin expression and dif-
fuse histology (sporadic: P  .001; familial: P  .017; Table 4).
In addition, there were no differences when comparing
E-cadherin immunohistochemistry (IHC) pattern in GCs carrying
overall or specific CDH1 alterations with the pattern in those without
alterations (P  .479 and P  .275, respectively; Table 3). These results
revealed that the CDH1 alterations analyzed do not generate a specific
E-cadherin IHC pattern and, more importantly, that 60% of GCs
without E-cadherin expression and approximately 70% of GCs with
aberrant expression are negative for CDH1 alterations (Appendix
Table A5, online only).
DISCUSSION
GC is a highly heterogeneous disease where even similar clinical and
pathologic features lead to distinct outcomes.7,9,11,36 These observa-
tions indicated that staging systems, based on clinical and pathologic
Table 3. Comparison of Clinicopathologic Variables With CDH1 Alterations in Patients With GC
Variable
Total No. of
Patients
(N  246)
CDH1 Overall Alterations CDH1 Epigenetic and Structural Alterations
Positive
(n  77)
Negative
(n  169)
P
Epigenetic
(n  51)
Structural
(n  26)
Negative
(n  169)
P
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Age, years
Mean 68.05 69.1 67.6 69.7 67.9 67.6
Standard deviation 10.9 11.8 10.4 13.3 8.5 10.4
Sex .110 .004
Male 143 51 66.2 92 54.4 28 54.9 23 88.5 92 54.4
Female 103 26 33.7 77 45.6 23 45.1 3 11.5 77 45.6
Liver or peritoneal metastases .920 .218
Present 20 6 7.8 14 8.3 2 3.9 4 15.4 14 8.3
Absent 226 71 92.2 155 91.7 49 96.1 22 84.6 155 91.7
Radicality of resection .502 .049
R0 181 54 70.1 127 75.1 40 78.4 14 53.8 127 75.1
R1/2 65 23 29.9 42 24.8 11 21.6 12 46.1 42 24.8
Extent of gastrectomy .680 .100
Partial 150 45 58.4 105 62.1 34 66.7 11 42.3 105 62.1
Total 96 32 41.6 64 37.9 17 33.3 15 57.7 64 37.9
Lymphadenectomy 1.0 .737
D1 91 28 36.4 63 37.3 17 33.3 11 42.3 63 37.3
D2/3 155 49 63.6 106 62.7 34 66.7 15 57.7 106 62.7
Lauren histotype .108 .007
Intestinal 160 44 57.1 116 68.6 24 47.1 20 76.9 116 68.6
Diffuse 86 33 42.9 53 31.4 27 52.9 6 23.1 53 31.4
Depth of invasion .436 .695
pT1 17 3 3.9 14 8.3 2 3.9 1 3.8 14 8.3
pT2 93 31 40.3 62 36.7 22 43.1 9 34.6 62 36.7
pT3-4 136 43 55.8 93 55.0 27 52.9 16 61.5 93 55.0
Lymph node involvement .021 .042
Absent (pN0) 72 15 19.5 57 33.7 8 15.7 7 26.9 57 33.7
Present (pN) 173 62 80.5 111 65.7 43 84.3 19 73.1 111 65.7
Stage .029 .155
I 57 10 13 47 27.8 6 11.8 4 15.4 47 27.8
II 41 15 19.5 26 15.4 10 19.6 5 19.2 26 15.4
III 106 41 53.2 65 38.5 28 54.9 13 50.0 65 38.5
IV 40 10 13 30 17.8 6 11.8 4 15.4 30 17.8
GC familial aggregation .371 .372
Positive 72 26 33.8 46 27.2 19 37.3 7 26.9 46 27.2
Negative 174 51 66.2 123 72.8 32 62.7 19 73.1 123 72.8
E-cadherin IHC† .275 .479
Absent 30 12 19.0 18 12.5 8 20 4 17.4 18 12.5
Aberrant 152 46 73.0 106 73.6 30 75 16 69.6 106 73.6
Normal 25 5 7.9 20 13.9 2 5 3 13.0 20 13.9
Abbreviations: GC, gastric cancer; IHC, immunohistochemistry.
R0 resection indicates a microscopically margin-negative resection.35 R1/R2 resections indicate different grades of positivity for tumor after surgery (primary
tumor, regional nodes, and microscopic/macroscopic margin involvement).35
†Only 207 patients were analyzed for IHC; the percentages of CDH1-positive, -negative, epigenetic, and structural alterations were calculated by adjusting the total
number of alterations to 63, 144, 40, and 23, respectively.
Corso et al
872 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 193.136.52.11 on January 19, 2018 from 193.136.052.011
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
findings, may have reached their limit of usefulness and impelled the
need for molecular biomarkers, as an added value, to predict patients’
outcome and treatment.
The present study encompasses a large series of sporadic and
familial GCs (negative for CDH1 germline mutations) systematically
analyzed for somatic CDH1 structural and epigenetic inactivating
mechanisms. Furthermore, this study systematically correlates the
molecular data with patient survival, clinicopathologic parameters,
and E-cadherin IHC expression.
The main findings of the present study indicate the following:
somatic CDH1 alterations occur in approximately 30% of all GCs
analyzed (approximately 20% epigenetic, approximately 10% struc-
tural); CDH1 structural alterations underlie the worst survival rate of
patients with GC overall; patients with FIGC with tumors with struc-
tural alterations had the worst overall survival rate; HDGC tumors
harbored exclusively CDH1 promoter hypermethylation (approxi-
mately 50%); specific CDH1 alterations underlie distinct GC clinico-
pathologic features; and overall or specific CDH1 alterations are not
associated with a distinct pattern of E-cadherin immunoexpression.
These and other findings will be discussed in more detail here.
The results herein reported may change the paradigm thus far
described for CDH1 alterations in GC. In the sporadic context,
E-cadherin abnormalities have been, to date, mainly associated with
the diffuse type of GC, and CDH1 somatic mutations and promoter
methylation have each been reported in more than 50% of these
patients.26,27,29,33,34,37 In diffuse GCs, we report epigenetic alterations
(methylation only) in 25.4%, somatic mutations in 4.5%, and LOH in
4.5% (structural alterations). These frequencies are lower than
most earlier reported frequencies, but are similar to those recently
reported in several independent series.28,30,31 Discrepancies are
most likely a result of different methodologies used. Interestingly,
we demonstrate that CDH1 somatic epigenetic and structural al-
terations are as frequent in intestinal as in diffuse GC, suggesting
histotype independence.
In the familial setting, tumors from HDGC families lacking
germline CDH1 mutations displayed exclusively CDH1 promoter
methylation in frequencies comparable to those previously pub-
lished for HDGC carriers of CDH1 germline mutations.23 We
herein report for the first time, to the best of our knowledge, that
tumors from FIGC families also present somatic CDH1 epigenetic
and structural alterations in frequencies similar to those of patients
with sporadic GC.
Importantly, GCs with epigenetic or structural CDH1 alterations
or negative for CDH1 alterations revealed an unequal impact on
patient survival. Patients with tumors with CDH1 structural altera-
tions displayed a significantly poorer survival rate than patients with
tumors negative for CDHI alterations or patients with tumors with
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Fig 2. Details of the molecular analysis performed in gastric cancer (GC) samples and survival rates of patients with GC. Kaplan-Meier curves show the probability
of overall survival for patients with familial intestinal GC (FIGC), hereditary diffuse GC (HDGC), sporadic intestinal GC, and sporadic diffuse GC according to CDH1
alterations (epigenetic, structural, or negative).
Table 4. E-Cadherin Immunoexpression in Sporadic and Familial GCs
GC Setting and
Histologic Type
No. of
Patients
E-Cadherin Immunoexpression
P
Absent Aberrant Normal
No. % No. % No. %
Sporadic 147 .001
Intestinal 95 4 4.2 74 77.9 17 17.9
Diffuse/mixed 52 14 26.9 36 69.2 2 3.8
Familial 60 .017
FIGC 43 5 11.6 32 74.4 6 14
HDGC 17 7 41.2 10 58.8 0 0
Total 207 30 14.5 152 73.4 25 12.2
NOTE. Scoring criteria were as follows: absent, E-cadherin not expressed;
aberrant, cytoplasmic or heterogeneous staining of E-cadherin; and normal,
complete E-cadherin membrane staining.
Abbreviations: FIGC, familial intestinal gastric cancer; GC, gastric cancer;
HDGC, hereditary diffuse gastric cancer.
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epigenetic CDH1 alterations. In line with these findings, Gamboa-
Dominguez et al38 observed that patients with GC displaying CDH1
exon 8/9 deletions (structural) have a worse clinical evolution and a
shorter overall survival. An adverse prognostic effect of CDH1 pro-
moter hypermethylation in patients with diffuse GC has also been
reported, but no structural alterations were reported in that series.34
When we explored in depth the survival rates of patients belong-
ing to different clinical settings and histologic types, the most striking
finding was that patients with FIGC with tumors with structural alter-
ations had the worst overall survival. This observation indicates that
CDH1 somatic alterations are a novel and unexpected feature of
FIGCs and, more importantly, allows the stratification of patients with
FIGC into subsets with completely different clinical outcomes. Avail-
able data on familial history associated with survival of patients with
GC has remained largely inconclusive.39-41 One of the latest reports
addressing this issue demonstrated a favorable prognosis for patients
with a positive family history of GC, whereas others did not.39-41 These
controversial results may have been affected by different strategies in
selecting the study population and, mainly, by inconsistent definitions
and clinical criteria for family history, precluding comparison of trust-
worthy results. In light of our own findings, molecular variables such
as CDH1 alterations may be crucial to better define the survival of
patients with family history.
Apart from the impact of CDH1-specific alterations on survival
of patients with GC, these alterations also underlie other clinicopath-
ologic features. Tumors with CDH1 epigenetic alterations were more
often of the diffuse histotype, and patients more frequently displayed
lymph node metastases. These observations suggest that superex-
tended lymphadenectomy may be an adequate procedure in these
patients.42 However, patients with tumors with CDH1 structural al-
terations more often had the intestinal type (76.9%), and despite the
generally accepted better prognosis,43 these patients had the worst
survival, as previously discussed. Furthermore, these patients were
mainly men and had been more frequently subjected to R1/2 radical
resections, indicating the presence of a more aggressive disease. There-
fore, screening of CDH1 alterations at the biopsy stage, concomitantly
with histologic classification and both faster and more radical surgery,
may bring benefit to the approximately 10% of patients with GC who
belong to this specific group (Appendix Fig A3, online only).
In parallel, we also verified that approximately 68% of patients
with altered E-cadherin expression were negative for CDH1 altera-
tions, showing that IHC, per se, is not an efficient method to infer
E-cadherin molecular alterations and indicating other transcriptional/
post-transcriptional regulatory mechanisms.44-47 Following this idea,
we have recently reported that miR-101 downregulation with conse-
quent EZH2 upregulation constitutes an additional mechanism by
which E-cadherin becomes dysfunctional, mainly in intestinal-type
GC retaining allele(s) untargeted by classical CDH1 inactivat-
ing mechanisms.28
In conclusion, our data provide, for the first time to our knowl-
edge, a detailed analysis of somatic CDH1 alterations in different
clinical settings and histologic types of GC, highlighting subsets of
patients with distinct clinical outcomes. In particular, this work de-
fined a group of patients (FIGC with CDH1 structural alterations)
with the worst prognosis among all GCs analyzed. The presence of
CDH1 epigenetic and structural alterations in a diagnostic/preopera-
tive biopsy may provide clinical utility and improve patient manage-
ment, particularly to infer the prognosis of GC and the pattern of
tumor dissemination.
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